- Timo grimmer is in the team - All endpoints of the clinical trial were reached I firmly believe that the drug works and that the CEO has done a good job no matter how much he is criticized.

Anavex's A2-73 Blarcamesine's trial results on 2 previously completed adult phase-3 trials were highly successful.

$AVXL amazing avxl still in singke digits after a supposedly amazing “pivotal” trial readout 🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️😂😂😂

$AVXL The trial met both co-primary and secondary endpoints showing statistically significant reduction of clinical decline as measured by those endpoints.

$AVXL Australia trial data meets the gold standard.

The results were excellent on the 2 completed adult trials, and because the 3rd trial is pediatric and early on the disease, they are expected to perform even better.

2-73 has orphan designation for Rett which combined with the multiple Rett trials and it very good safety record should make it a great candidate for AA.

This company has yet to fail to meet endpoints on any trial and the thousands of papers on the MOA eliminates fraud with science, and the company is in great fiscal shape so no shenanigans there.

Sava has potential and the phase 3 results will show the truth.

Monday morning pre-market screamer 😱 candidates: 🚨🚨🚨💎💎💎🔥🔥🔥 $TCBP Phase 2 update still pending-huge potential on this nano float $BOXD over $1 easy $ALLR PT $.50 $HTGM she’s ready for another big run This week was very good to me.

SIMILAR SETUP TO $AMAM, $HTGM, $APVO, $APCX Volume increasing since last week ✅ Low float recent IPO ✅ Strong future trial pipeline ✅ Time for the next leg up towards IPO price!

SHOULD be some awesome opportunities this week, study study study!

$ATNM positive news in their acute myeloid leukemia trials 👇🏼 53% 1-year Overall Survival and 32% 2-year Overall Survival are approximately double outcomes with current approaches It's time to get in before we blast off to $12+ next!

Time-release formulations are associated with the added advantages of convenience of dosing, improved compliance, and less fluctuation in blood levels across the course of the day.

$BCRX In both the SAD and the MAD studies, oral BCX9250 was safe and well tolerated, with no serious adverse events, No safety signals were seen.

Nice and consistent for the median patient FYI the poster this chart is from notes that none of these patients are from the clinical trial

$BCRX so they hit their Q4 numbers, had stellar phase IA results and guided for a 70Mil increase in revenue in 202e.

$BCRX it’s a great time to be a BioCryst shareholder, oooup FDA clinical pause, hey we still have 9250, fda clinical lift, 9250 is too tough, 9930 is too tough…

A trial involving 450 children in Burkina Faso found that three doses of the vaccine, plus a booster shot, were up to 80 percent effective at preventing infection.

BCX10013 pre clinical may be impressive

$BCRX GSK: ANNOUNCES POSITIVE PHASE IIA STUDY RESULTS FOR A NEW FIRST-IN-CLASS CANDIDATE MEDICINE FOR PATIENTS WITH TUBERCULOSIS * GSK - TREATMENT WAS GENERALLY WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS IDENTIFIED

$BCRX $ATNM $ATNM positive Phase 3 for AML and only 24 million float!!

Management revenue growth product execution Great research team market competitiveness against it's competition size and future growth of market clinical trials BCRX is a 10 on all fronts